# Guidance for Industry and Investigators on Enforcement of Safety Reporting Requirements for Investigational New Drug Applications and Bioavailability/Bioequivalence Studies; Availability
> **Food and Drug Administration** · Notification of guidance. · Published 2011-06-07 · 76 FR 32863
## Document
- **Document number:** 2011-13950
- **Category:** fda-drug
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 76 FR 32863
- **CFR reference:** 21 CFR 312
- **Publication date:** 2011-06-07
- **HHS docket:** Docket No. FDA-2010-D-0482
## Abstract

The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry and investigators entitled "Enforcement of Safety Reporting Requirements for INDs and BA/BE Studies." This guidance is intended to inform sponsors and investigators of FDA's intent to exercise enforcement discretion regarding the reporting requirements in the final rule, "Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans" (75 FR 59935, September 29, 2010), until September 28, 2011. This action is being taken in response to requests from sponsors to extend the March 28, 2011, effective date of the final rule. FDA expects all sponsors and investigators to be in compliance with the new regulations no later than September 28, 2011.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2011/06/07/2011-13950/guidance-for-industry-and-investigators-on-enforcement-of-safety-reporting-requirements-for)
---
*AI Analytics · CC0 1.0*